ASCO GU 2021 Archives

A patient with cancer receives palliative care.

ASCO GU 2021

Palliative Care Use in Advanced Renal Cell Carcinoma Linked to Socioeconomic Groups

By

Jessica Nye, PhD

February 15, 2021

Researchers sought to determine accessibility and use of palliative care among patients with advanced renal cell carcinoma.

FDA label changes for certain immunotherapies may have prompted a marked increase in the use of PD-L1 assays.

ASCO GU 2021

Demographic Factors With Stage at Diagnosis and Use of Treatment in Bladder Cancer

By

Vicki Moore, PhD

February 13, 2021

Researchers sought to identify social disparities in diagnosis and treatment among patients with bladder cancer.

A Call for Improving the Quality of Cancer Care in Geriatric Patients

ASCO GU 2021

Geriatric Assessment Predictive of Outcomes of Radical Cystectomy for Bladder Cancer

By

Vicki Moore, PhD

February 13, 2021

Prospective cohort study sought to determine the association between impairments identified through GA and outcomes of radical cystectomy for bladder cancer.

ASCO GU 2021

Bladder Pressure May Influence Intravesical Drug Delivery

By

Vicki Moore, PhD

February 13, 2021

Using porcine bladders, researchers investigated whether bladder pressure affects the extent to which gemcitabine penetrates the bladder wall with this treatment modality.

Micrograph of Invasive urothelial carcinoma high grade.

ASCO GU 2021

Tumor Mutational Burden, Immune-Related Adverse Events in Metastatic Urothelial Cancer

By

Vicki Moore, PhD

February 13, 2021

Researchers analyzed data from patients with metastatic urothelial cancer to determine whether tumor mutation burden was associated with immune-related AEs among patients treated with immune checkpoint inhibitors.

ASCO GU 2021

Perceptions of Goals, Challenges Regarding Shared Decision-Making in Bladder Cancer Care

By

Vicki Moore, PhD

February 12, 2021

Results of a survey show differences between patients and healthcare providers regarding key aspects of bladder cancer treatment and outcomes.

Though early-stage bladder cancer is infrequently fatal, the decrease in recurrence rates has a mean

ASCO GU 2021

Some Outcomes for Patients Undergoing Radical Cystectomy Differ Between the Sexes

By

Vicki Moore, PhD

February 12, 2021

Researchers present data comparing outcomes of radical cystectomy for female and male patients with bladder cancer.

The high cost of CAR-T therapy concerns patient advocates who worry about the "financial toxicity" i

ASCO GU 2021

Discussions on Financial Toxicity, Impact on Work Need Improvement, Report Patients With Prostate Cancer

By

Vicki Moore, PhD

February 12, 2021

Study reveals patients’ and survivors’ perception of discussions with their healthcare team regarding options, costs, and impact on work related to prostate cancer treatment.

ASCO GU 2021

Early Quality-of-Life Declines Predict Need for Intervention in Patients With Prostate Cancer Receiving Radiotherapy

By

Vicki Moore, PhD

February 12, 2021

Using the EPIC-CP tool, researchers sought to determine if early patient reports of quality of life improved over time in patients undergoing radiotherapy for prostate cancer.

Close to 60% of all patients with VHL will develop RCC or renal cysts.

ASCO GU 2021

Bone-Targeted Therapies and Incidence of Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma

By

Vicki Moore, PhD

February 11, 2021

A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.